Analyst Price Target is $24.25
▲ +127.27% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for PepGen in the last 3 months. The average price target is $24.25, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 127.27% upside from the last price of $10.67.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in PepGen.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.